Jiangsu Recbio Technology Co., Ltd. (HKG:2179)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
5.10
+0.03 (0.59%)
Apr 28, 2026, 1:35 PM HKT
-32.72%
Market Cap 3.13B
Revenue (ttm) 14.16M
Net Income (ttm) -679.25M
Shares Out 616.81M
EPS (ttm) -1.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,500
Average Volume 5,200
Open 5.09
Previous Close 5.07
Day's Range 5.07 - 5.10
52-Week Range 3.40 - 9.30
Beta -0.09
RSI 61.92
Earnings Date Mar 24, 2026

About Jiangsu Recbio Technology

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People’s Republic of China. The company develops vaccines for the treatment of cervical cancers, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines targeting HPV type 6/11, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that i... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 491
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2179
Full Company Profile

Financial Performance

In 2025, Jiangsu Recbio Technology's revenue was 12.73 million, a decrease of -52.88% compared to the previous year's 27.01 million. Losses were -610.39 million, 9.49% more than in 2024.

Financial numbers in CNY Financial Statements

News

There is no news available yet.